NASDAQ:INNT Innovate Biopharmaceuticals (INNT) Stock Price, News & Analysis → Why Big Pharma is Investing Billions in This Biotech (From Behind the Markets) (Ad) Free INNT Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range N/A50-Day Range$0.56▼$1.4252-Week Range N/AVolume919 shsAverage Volume525,982 shsMarket Capitalization$8,000.00P/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisCompetitorsHeadlinesSocial MediaStock AnalysisCompetitorsHeadlinesSocial Media Get Innovate Biopharmaceuticals alerts: Email Address Ad InvestorPlaceHas Jeff Bezos Found the Next Nvidia?If you’ve sat back and watched companies like Nvidia and AMD soar over 2,000% over the past several years… And wondered what was next… This is a fast-moving story, but if you want the chance to profit alongside Jeff Bezos in the next big tech trend, go ahead and…Click Here for Full Details About Innovate Biopharmaceuticals Stock (NASDAQ:INNT)Innovate Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for autoimmune and inflammatory diseases. The company's lead product candidate is INN-202 that has completed Phase IIb clinical trial for the treatment of celiac disease. It also develops INN-108, which has completed Phase I clinical trial to treat mild-to-moderate ulcerative colitis; INN-217 for the treatment of non-alcoholic steatohepatitis and microbiome; and INN-289 to treat crohn's disease, as well as product for the treatment of alcoholic steatohepatitis (ASH). In addition, the company holds rights for INN-329, a formulation of secretin that is used to enhance visualization in magnetic resonance cholangiopancreatography procedures that is in Phase III clinical trial. The company has a research collaboration with Massachusetts General Hospital for the treatment of ASH. Innovate Biopharmaceuticals, Inc. is based in Raleigh, North Carolina.Read More Ad InvestorPlaceHas Jeff Bezos Found the Next Nvidia?If you’ve sat back and watched companies like Nvidia and AMD soar over 2,000% over the past several years… And wondered what was next… This is a fast-moving story, but if you want the chance to profit alongside Jeff Bezos in the next big tech trend, go ahead and…Click Here for Full Details INNT Stock News HeadlinesApril 27, 2024 | bizjournals.comAll about preservation — Innovation Campus Phase 1April 26, 2024 | finance.yahoo.comRakovina Therapeutics Inc. Announces 2023 Financial Results and Provides Corporate UpdateApril 30, 2024 | InvestorPlace (Ad)Has Jeff Bezos Found the Next Nvidia?If you’ve sat back and watched companies like Nvidia and AMD soar over 2,000% over the past several years… And wondered what was next… This is a fast-moving story, but if you want the chance to profit alongside Jeff Bezos in the next big tech trend, go ahead and…April 23, 2024 | finanznachrichten.deCNS Pharmaceuticals, Inc.: CNS Pharmaceuticals to Present at the LSX World Congress 2024April 22, 2024 | finance.yahoo.comSystImmune, Inc. Appoints Dr. Jie D'Elia as Chief Executive OfficerApril 19, 2024 | msn.comInnovate Change - best online casinos review by the experts 2024April 18, 2024 | finanznachrichten.deOcular Therapeutix, Inc.: Ocular Therapeutix Announces Positive Topline Phase 1 Data for AXPAXLI in Diabetic RetinopathyApril 15, 2024 | finance.yahoo.comThird Harmonic Bio Inc CEO Natalie Holles Sells 13,558 SharesApril 30, 2024 | InvestorPlace (Ad)Has Jeff Bezos Found the Next Nvidia?If you’ve sat back and watched companies like Nvidia and AMD soar over 2,000% over the past several years… And wondered what was next… This is a fast-moving story, but if you want the chance to profit alongside Jeff Bezos in the next big tech trend, go ahead and…April 15, 2024 | finance.yahoo.comAmerican Thoracic Society Selects Vasomune Therapeutics, Inc., to Present the AV-001 Development Update at the 2024 Respiratory Innovation SummitApril 12, 2024 | tmcnet.comUniversity of Phoenix Office of Educational Equity Leadership Presents at 2024 OLC Innovate ConferenceApril 10, 2024 | finanznachrichten.deMonopar Therapeutics Inc.: Monopar Initiates Radiopharma Phase 1 Clinical Trial for MNPR-101-Zr in Advanced Cancer PatientsApril 10, 2024 | finanznachrichten.deIN8bio, Inc: IN8bio Announces New Preclinical Data for Gamma-Delta nsCAR-T Cell Therapy Platform at AACR 2024April 9, 2024 | finance.yahoo.comNIIMBL Announces $10M for 8 New Biopharmaceutical Manufacturing ProjectsApril 9, 2024 | stockhouse.comSynaptogenix Increases Stake in Innovative Psilocybin Drug Discovery Company through its Partnership with Cannasoul AnalyticsApril 9, 2024 | tmcnet.comSyncromune® Inc. Presents Positive Results from SYNC-T™ SV-102 Phase 1 Trial at AACR Annual Meeting 2024April 4, 2024 | finance.yahoo.comCadenza Bio, Inc. Appoints Michael A. Panzara, MD, MPH, to its Board of DirectorsMarch 29, 2024 | finanznachrichten.deSAB Biotherapeutics, Inc.: SAB Biotherapeutics Reports Full Year 2023 Operating and Financial ResultsMarch 28, 2024 | finanznachrichten.deMonopar Therapeutics Inc.: Monopar Reports Fourth Quarter and Full-Year 2023 Financial Results and Recent DevelopmentsMarch 28, 2024 | finanznachrichten.deXtalPi Inc.: XtalPi to Present the Latest Progress of Its AI Cancer Vaccine Design Platform at AACR 2024March 26, 2024 | finanznachrichten.deCognition Therapeutics, Inc.: Cognition Therapeutics Reports Year End 2023 Financial Results and Provides Business UpdateMarch 25, 2024 | finance.yahoo.comAptamer Sciences Inc. Files IND Application for Innovative Liver Cancer Treatment AST-201: A Promising Approach to Address Under Medical NeedsMarch 20, 2024 | markets.businessinsider.comJanux Therapeutics: A Strong Buy on Innovative Cancer Therapies and Solid FinancialsMarch 20, 2024 | finanznachrichten.deTFF Pharmaceuticals, Inc.: TFF Pharmaceuticals Announces Update on Clinical ProgramsMarch 20, 2024 | msn.comThe problems and promise within Syracuse’s innovation economyMarch 20, 2024 | markets.businessinsider.comBuy Rating Endorsed for Azitra Inc. on Strong Pipeline and Financial StabilityMarch 18, 2024 | finance.yahoo.comAlpine Immune Sciences Inc (ALPN) Reports Full Year 2023 Financial ResultsSee More Headlines Receive INNT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Innovate Biopharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/18/2019Today4/29/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolNASDAQ:INNT CUSIPN/A CIK1551986 Webwww.innovatebiopharma.com Phone919-275-1933FaxN/AEmployees8Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-27,050,000.00 Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on Assets-234.42% Debt Debt-to-Equity RatioN/A Current Ratio0.35 Quick Ratio0.35 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($0.27) per share Price / BookN/AMiscellaneous Outstanding Shares41,325,000Free FloatN/AMarket Cap$8,000.00 OptionableNot Optionable Beta-0.39 These 7 Stocks Will Be Magnificent in 2024With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.Get This Free Report Key ExecutivesMr. Sandeep Laumas M.D. (Age 50)CEO & Exec. Chairman Mr. Jay P. Madan M.S. (Age 53)Founder, Pres, Chief Bus. Officer, Interim Principal Fin & Accounting Officer and Director Dr. Christopher P. Prior (Age 66)Consultant Jerry Gardner M.D.Head of Clinical StrategyDr. Patrick H. Griffin (Age 64)Chief Medical Officer Key CompetitorsNovanNASDAQ:NOVNNVN LiquidationNASDAQ:NOVNQGenocea BiosciencesNASDAQ:GNCAHTG Molecular DiagnosticsNASDAQ:HTGMQKaleido BiosciencesNASDAQ:KLDOView All Competitors INNT Stock Analysis - Frequently Asked Questions How were Innovate Biopharmaceuticals' earnings last quarter? Innovate Biopharmaceuticals Inc (NASDAQ:INNT) issued its quarterly earnings results on Monday, March, 18th. The company reported ($0.11) earnings per share for the quarter, hitting analysts' consensus estimates of ($0.11). What other stocks do shareholders of Innovate Biopharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Innovate Biopharmaceuticals investors own include NIO (NIO), Corbus Pharmaceuticals (CRBP), AcelRx Pharmaceuticals (ACRX), Iterum Therapeutics (ITRM), SCYNEXIS (SCYX), Micron Technology (MU), Nabriva Therapeutics (NBRV), Neurotrope (NTRP) and This page (NASDAQ:INNT) was last updated on 4/30/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingCharles Payne’s Gift to Stock InvestorsUnstoppable ProsperityHe Is Giving Away BitcoinCrypto Swap ProfitsElon Musk Secret Crypto Plot ExposedCrypto 101 MediaForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm PressThe A.I. story nobody is telling you (Read ASAP)TradeSmith4 coins to be the “Next Bitcoin”True Market Insiders Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Innovate Biopharmaceuticals Inc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
